A revenue ranking tells you who is big. A broker, or a sourcing team at an AI data company, needs a different order: which companies generate the records AI buyers want, which of those records the company actually owns, and who inside can say yes. This page maps US pharma and its service ecosystem in that order, then shows how to work our scored list of US labs, CROs and life-science companies.
Found a target? Qualify it against micro1 and Mode rules in about 20 seconds.
Not all company data is worth the same. Our research shows AI labs pay most for the records of real work, held in the systems below. We identify which of these systems each company runs, and it is one of the most important factors in the AI Data Value Score.
Every company comes with the systems we identified, shown as tags. Company level only: we show which systems a company runs, never what is inside them.
Share of the 4,200 companies in this list with each data type. Among them, 15% run systems for CRM records, 11% for contracts and documents, 10% for work tickets and internal wikis, and 64% have been online for 10 years or more before 2023.
Counted over the companies a buyer gets in this list: verified active, checked for fit with the industry, highest AI Data Value Score first. Company level only: we show which systems a company runs, never what is inside them.
Niche lists go deeper than a sector list. Every company domain is verified active, each company was checked for fit with the niche, and companies are ranked by the AI Data Value Score. $2,500 per list, or $9,900 for 90 days of exclusive access.
Search for a list of pharmaceutical companies in the USA and you get the same names in the same order: the largest drug makers by sales, then a long tail sorted alphabetically. That list answers an investor's question, or a job seeker's. It does not answer the question a data broker or a partnership team at an AI data company is asking, which sounds more like this: where is there a large, owned, well-documented record of expert work, and is there someone at that company who can approve licensing a copy of it?
Pharma is an unusually rich place to ask. The industry runs on written procedure. Every batch is recorded step by step. Every deviation is investigated and closed with a documented root cause. Every adverse event report is triaged, coded and assessed, and every question from a physician gets a referenced answer. Regulators require much of this paperwork, so it exists, it is structured, and it goes back years. That is the kind of record AI buyers describe wanting: long, connected histories of how specialists reason and decide.
It is also an unusually hard place to close a deal. A large share of what pharma companies hold is patient data, a trade secret, or content that belongs to a client or a sponsor. Separating the record that might be licensable from the record that never will be is most of the work, and the split changes by segment. So this page goes segment by segment, then record by record, and then lists the questions to put in front of counsel before anyone mentions a buyer.
One industry label covers very different businesses. What a company makes decides which records it keeps. How big it is decides who signs. The fit labels below are our reading for a broker's time, not a buyer's verdict.
A rule of thumb that holds across all five: the further a company sits from the patient and the molecule, the more of its record it owns outright. A CRO's study data belongs to the sponsor, but its SOPs, training program and the way it runs projects are its own. A testing lab's results belong to its clients, but its method validation know-how and its support history are its own. A software vendor to quality teams may own almost everything it holds, apart from customer content. When you sort a prospect list, sort by that distance first and by company size second.
These are the records that come up when sourcing teams describe what they want from regulated industries. Ownership here is the usual pattern, not a rule: each company's contracts decide it.
| Record family | Typical systems | What is inside | Usually owned by | Why AI buyers care |
|---|---|---|---|---|
| Quality systems | Electronic QMS, document control, training management | SOPs, deviations, investigations, corrective and preventive actions, change controls, audit findings, training records | The company, for its own procedures. The client, for product records at a CDMO or CRO | An investigation is written expert reasoning: a problem, the evidence, a conclusion and a fix |
| Regulatory submissions | Regulatory information management, publishing tools, document management | Applications, amendments, annual reports, answers to agency questions, labeling | The sponsor that filed them, even when a consultancy or CRO wrote them | Long technical writing in a strict structure, plus the questions an agency asked and how they were answered |
| Manufacturing batch records | MES, electronic or paper batch records, ERP | Master and executed batch records, in-process checks, equipment logs, line clearance, exceptions | The product owner, for product data. The manufacturer, for its own equipment and methods | Step-by-step procedure with checks and exceptions, a close match for process and agent training |
| Pharmacovigilance | Safety databases, case intake, literature screening | Adverse event cases, narratives, coding, causality assessments, periodic safety reports, signal reviews | The company that holds the marketing authorization. Service providers process cases for it | A repeated expert workflow from intake to assessment. Also full of patient health information |
| Medical information | Medical information systems, contact center tools, content libraries | Questions from physicians, pharmacists and patients, standard response documents, references | The company that markets the product. Vendors often run it under contract | Question and referenced answer pairs written by specialists. Inquiries carry personal and sometimes health data |
| Support | Helpdesk, CRM, customer portals, knowledge bases | Customer and technical support tickets, order issues, instrument and software support, how-to articles | Usually the company itself | Long, specialist conversations about real problems, and usually the easiest family to scope and de-identify |
Brokers new to pharma go straight for the regulated record: submissions, batch records, safety cases. Those are the most impressive and the hardest to license. The record that moves most easily is often the plainest one. A company that sells instruments, reagents, software or testing services to labs has years of support tickets in which specialists explain a failed run, a calibration drift or a validation question to another specialist. Those threads are the company's own, they rarely contain patient data, and they can be scoped by product line and date. In the free labs preview, support tickets and chat transcripts often appear among the likely data assets.
Raw records are the start, not the whole value. Practitioners say evaluations are worth about 10 times raw data, and full environments reach six to eight figures. Pharma workflows translate well into both. A deviation investigation, a safety case or a medical information response has a clear input, a documented expert process and an output a reviewer can check. For a data company, that means a pharma services firm may be worth more as a partner whose specialists help build and grade tasks than as a one-time seller of an archive. For a broker, it means the introduction is worth framing around the company's expertise, not only its files.
None of this is legal advice. These are the questions to put to the company's own lawyer, and to yours, before anyone drafts a manifest. If the honest answer to any of them is "we do not know", the record stays out of scope.
The buyer programs that pay referral fees publish who they want. Their published rules point at mid-size companies, which is where much of the pharma service ecosystem sits.
Buyer facts as published, checked 7 October 2026: micro1 "$100K-$2M+ for approved data packages", Mode "$100K-$5M". These are published ranges, not offers. The trade-off is real: a mid-size service company has less data than a global drug maker, and some of what it holds belongs to clients. Smaller, owned and decidable usually beats larger, shared and stuck.
The free preview of the list shows 5 visible rows. They are companies checked for this industry, and they can change, so we do not copy them onto this page. See the live preview for the rows as they stand today. The list itself can be bought once, from $199 a list (the 3,000+ highest-scored companies), as a snapshot with no updates. The API plans do not include lists; they score the domains you send, which is how you check pharma companies you find outside the file.
Each visible row shows the company website, its AI Data Value Score and grade, its activity status, the year it came online and the data it likely holds. Every company in the preview carries the category "Life sciences, pharma and labs". Live counts for the list are on the lists page, because the list grows as more companies pass our checks.
Notice what the preview does not do: it does not sort companies into the five segments above. A domain and a category do not tell you whether a company is a manufacturer, a service provider, a software vendor or a supplier to labs, and we will not guess on a public page. That sorting is your first job as a broker, and it takes a few minutes per company on its own website. The value of the list is the order: it puts the companies that likely hold the most of what AI buyers want first, with their history and status beside them.
Look also at the dates in the online since column. Long, continuous history is one of the nine factor groups in the score, and it lines up with what Mode publishes: several years of records. A company that has run a support desk for two decades has a deeper archive than one that opened last year, even if both look similar today.
The one-time download holds the top 3,000+ by AI Data Value Score, selected from 22,954 US domains in this sector of our index, which is where most brokers start: the strongest candidates, already in order. Rank is not everything in pharma services, where a small bioanalytical lab, a regulatory consultancy or a software supplier to labs can be an easier partner than a larger name, even if its score sits further down. If you plan to tag segments yourself and push service providers up, start from the file, then score the providers you already know that are not in it: one at a time in the demo, or in batches of up to 100 domains through the API on any plan.
Every AI Data Value Score gives a company a score from 0 to 100, a grade, the data it likely holds, its history and an activity status. The nine factor groups are history, scale, knowledge assets, operational systems, customer systems, organization, industry value, expertise and activity status.
The company looks like it is trading normally. Next step: qualify it against published buyer rules, then work out who signs.
Pharma services consolidate often. If a lab or CRO was bought, the parent may now control the systems and the data policy. Find out who owns the records before you pitch anyone.
The domain no longer presents an operating company. Treat it as history, not a target, unless you can establish who controls whatever records survive.
The site could not be reached when it was checked. Check again later before drawing any conclusion about the company.
A working order for a broker or a data company's sourcing team, using only company-level information.
Buy the US labs, CROs and life-science list once as a CSV snapshot, from $199 a list (the 3,000+ highest-scored companies), best first. Pharma companies you found yourself go through the API in batches: up to 100 domains per call, one lookup per domain, on every plan.
Set a minimum score, keep companies marked active, and set aside anything winding down or acquired until you know who controls it now.
Open each company's site and tag its segment. Push service providers, labs, software and instrument companies up; push anyone whose record is mostly patient data down.
Run each survivor through check your company. It reads public pages and compares team size, location, history and systems with micro1 and Mode rules, with quotes, in about 20 seconds.
Only with consent from someone who can speak for the company, and only through each program's own referral process. Read data referral programs for the published terms.
# Any plan: score up to 100 of your own domains in one call curl -X POST -H "X-API-Key: YOUR_KEY" -H "Content-Type: application/json" \ -d '{"domains": ["bioanalytical-lab.example", "regulatory-consult.example", "lab-software.example"]}' \ "https://www.selldatatoai.com/api/v1/score/batch" { "id": "b_(batch id)", "status": "done", "total": 3, "lookups_charged": 3, "results": [ { "domain": "bioanalytical-lab.example", "status": "done", "result": { "data_asset_score": 63, "grade": "C", "status": "active", "history": { "first_seen_year": 2004, "years_online": 22 }, "likely_data_assets": [ { "type": "knowledge_base", "confidence": "high" }, { "type": "research_records", "confidence": "medium" } ] } } (two more results, in the order you sent them) ] }
Last updated: 8 October 2026. Payment by PayPal or card. The plans score the domains you send and differ only by lookups; batch scoring of your own domain lists is on every plan. No plan includes a company list: the list is a one-time file, set out under the plans. Your API key appears in your dashboard after payment, not by email. Full details on pricing.
| Purchase | 1 list | 2 lists | 3 lists | 5 lists | Each further list | All 21 lists |
|---|---|---|---|---|---|---|
| One-time price | $199 | $379 | $539 | $799 | +$199 | $3,900 |
Buy the US labs, CROs and life-sciences list: from $199 a list (the 3,000+ highest-scored companies)
Referral fees in this market are published and large. micro1 publishes "earn $50,000" per referred company with "no cap", paid after onboarding plus a minimum revenue threshold. Mode publishes "$50K per referral". All as published, checked 7 October 2026.
The terms matter as much as the amounts. micro1's terms give it sole discretion over every referred company, allow clawbacks, forbid sharing payouts with the company you refer, and forbid presenting yourself as micro1's partner. Read each program's terms before your first introduction, not after your first close.
Pharma adds its own layer. A company that runs regulated systems will ask hard questions early, and a broker who cannot answer them loses the room. Arrive knowing which segment the company is in, which of the six record families it likely holds, which of those are off limits, and which buyer program's published rules it meets. That is what the checklist covers, and none of it needs anything beyond company-level information.
One more point of conduct. You never handle the data. The company signs with the buyer, scopes the records with the buyer, and gets paid by the buyer. Your job ends at a qualified, consented introduction. For the roles in this market, read what is an AI data broker.
No. This page maps the segments of US pharma and the records each one keeps, for people who find data partners. The company list closest to pharma is our US labs, CROs and life-science companies list, one of 26 US industry lists we sell, and a free preview of it is public. Any pharmaceutical company outside that list can be scored one at a time in the demo or through the API.
Often mid-size service companies rather than the largest drug makers: CROs, testing and bioanalytical labs, CDMOs, regulatory and quality consultancies, and software and instrument suppliers to labs. They tend to own their procedures, training and support history outright, they sit inside the team sizes buyer programs publish, and a founder or COO can usually decide.
Treat it as out of scope until the company’s own counsel says otherwise. Trial participant data, adverse event cases and patient inquiries are covered by consent forms, contracts and health privacy law, and much trial data belongs to the sponsor rather than the company holding it. This page lists the questions to ask; it is general information, not legal advice.
Big pharma holds the deepest records but has the longest path to a yes: central data governance, internal AI programs, global privacy teams and a payout that is small next to its budgets. When a company that size licenses data, it can talk to AI labs directly and has little need for an introduction.
The API plans score the domains you send and differ only by lookups. Basic $99 a month: 5,000 lookups. Pro $299 a month: 25,000 lookups. Scale $799 a month: 100,000 lookups. Batch scoring of your own domain lists is on every plan, up to 100 domains per call, one lookup per domain. No plan includes a company list. The US labs, CROs and life-science list is sold only as a one-time file, from $199 a list (the top 3,000+ companies of the sector by AI Data Value Score), a CSV snapshot with no updates; download links are emailed right after payment, valid 30 days with 10 downloads per file. Payment is by PayPal or card; on a plan, the API key appears in your dashboard after payment.
Whether the company looks active, winding down or acquired, parked, or unreachable. In pharma services, where companies are often bought and merged, it tells you early whether the decision may now sit with a parent company, before you spend time on an introduction.
No. The score is an estimate from public signals of how valuable the data a company is likely to hold is to AI buyers. It is not a valuation, not an offer and not a sign that the company wants to sell. Use it to decide which companies to look at first, then qualify each one.
No. Everything we provide is company level: the domain, the score, the grade, the data the company likely holds, its history and its activity status. We do not provide names, emails or phone numbers.
See the free preview of the scored labs and CROs list, score any pharma company in the demo, and qualify a target against published buyer rules before you spend an hour on it. When you want more than the preview, buy the list once, from $199 a list (the 3,000+ highest-scored companies), and score the companies you find outside it through the API in batches.